张江独角兽，完成超6亿元融资 | 融资周报（2025年第34期）

Financing Overview - A total of 23 financing events occurred in Shanghai this week, with Zhangjiang accounting for 7 and Lingang for 2 [2] - The financing amount disclosed this week reached approximately 1.731 billion yuan, with 6 out of 23 events revealing their amounts [4] - The number of financing events increased by 5 compared to the previous week, which had 18 events [4] Company Dynamics - YaoTang Biotech announced research results on LNP-mRNA mediated in vivo gene editing of hematopoietic stem cells on August 12 [3] - On September 4, RuShen Robotics was selected for Tencent's 2025 Silver Technology Partner Program [3] - HengRui Medicine's subsidiary received approval for its first mRNA gene drug Phase II clinical trial on September 10 [5] - The China-Russia Medical Technology and Equipment Cooperation Center was established in Pudong on September 11 [5] - AstraZeneca's long-acting C5 complement inhibitor was launched in China on September 12 [5] Financing Rounds - The majority of financing events this week were in the angel round, totaling 9, followed by 7 in the A round [6] - B round financing reached a significant amount of 60 million USD [6] Industry Focus - Financing events this week spanned 11 industries, with the healthcare sector leading with 5 events, followed by artificial intelligence with 3 [9] Notable Financing Highlights - Zhenqu Technology completed over 600 million yuan in E round financing on September 8, led by Guotou Innovation and Guotou Investment [13] - Yijielike completed 60 million USD in B round financing on September 8, led by Longpan Investment [15] - New Electric Hero secured nearly 300 million yuan in strategic financing on September 10, exclusively invested by BAI Capital [17] - YaoTang Biotech completed over 300 million yuan in B round financing on September 10, led by AstraZeneca's CICC Medical Industry Fund [19] - RuShen Robotics completed several million yuan in angel+ round financing on September 9, exclusively funded by Daotong Investment [22] Hot Industry Focus - This week saw 5 financing events related to healthcare, including 2 in gene technology: Yijielike's 60 million USD B round and YaoTang Biotech's over 300 million yuan B round [24] - The surge in gene therapy investments is driven by policy support, with Shanghai's Science and Technology Commission announcing a special fund for gene therapy research, with a maximum grant of 5 million yuan per project [24]